Jafral will be supporting Phage Therapy 2024 Conference

It is a great pleasure to announce that JAFRAL is supporting the 7th World Conference Targeting Phage Therapy, to be held on June 20-21 in Malta.

About JAFRAL

JAFRAL is world leading Contract Development and Manufacturing Organization (CDMO) for Bacteriophages! JAFRAL offers development and manufacturing services for phage-based product to be used in different fields: Human therapeutics, Veterinary, Food industry, Agriculture, Cosmetics, etc.

JAFRAL, with its capacity of producing up to 200L batches, has long track record of producing GMP products, which also includes production of Clinical Trial Material for 12 Clinical trials, performed in US, EU and Australia. JAFRAL offers liquid formulations, spray drying and lyophilization.

Communication at Phage Therapy 2024

JAFRAL’s CEO, Dr. Frenk Smrekar, will give a short oral presentation on the “Production of Phage Products for Various Applications”.

In his talk, he will highlight the following:

  • High quality phage products
  • GMP/non-GMP production
  • Spray-drying / Lyophilization
  • Analytical testing
  • Clinical trial material
  • Production of compassionate use material

Join Dr. Smrekar on June 20-21 at Corinthia Palace Malta to know more about JAFRAL’s services and production process.

Company website: https://jafral.com/


Targeting Phage Therapy 2024
7th World Conference
June 20-21, 2024 – Corinthia Palace, Malta

Cellexus is a Supporter of Targeting Phage Therapy 2024

 

 

Cellexus is supporting the 7th World Conference Targeting Phage Therapy, scheduled on June 20-21 in Malta.

Who are Cellexus?

Cellexus International is a pioneering Scottish company specialized in manufacturing a range of bioreactors called the CellMaker. The CellMaker series stands out as the only single-use, purely airlift bioreactors available on the market today. The CellMaker offers efficient yet gentle mixing, allowing for easy scaling from 1.5L to 50L working volumes within a GMP-compliant system.

About CellMaker

Designed and optimised for various applications and cell types, the CellMaker systems utilize pure airlift technology to ensure efficient aeration while eliminating shear stress typically caused by impellers. This feature enables the production of clinical-grade biologics, ranging from viral vectors to phage therapies.

The single-use aspect of the CellMaker system not only streamlines operations, but also significantly reduces the economic and environmental impact of biologics manufacturing. By eliminating the need for cleaning and certifying reusable vessels, downtime is minimised, and resources such as energy, water, and chemicals are conserved.


How to collaborate with Cellexus?

Cellexus collaborates with academia and industry worldwide, offering customizable CellMaker systems tailored to meet specific process requirements while ensuring cost-effectiveness.

visit website: https://cellexus.com/


Targeting Phage Therapy 2024
7th World Conference
June 20-21, 2024 – Corinthia Palace, Malta

Who Attended Targeting Phage Therapy 2024?

Cellexus (Supporter)
Precision Phage (Supporter)
Jafral (Supporter)

Aumed
A&P Inphatec
AccessMDx
CO BIK
MB Pharma
PHAXIAM Therapeutics
Rime Bioinformatics
Phage Consulting
Intralytix
Invitris
MicrobiotiX 
Sciensano
TechnoPhage
Vivantes
Laboratorios Syva
ACD Pharma
Atlantic Technological University
Agricultural University of Athens
Agricultural University of Georgia
Bermuda Government
BG Klinikum Bergmannstrost Halle
Centro De Calidad Avícola Y Alimentación Animal De La Comunidad Valenciana
Charité Research Organisation GmbH
CHU Helora Mons
Ciberes-IDIBAPS
European Plotkin Institute for Vaccinology
Swiss Federal Institute of Technology Lausanne 
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology
Fudan University
Goethe University Frankfurt
Hannover Medical School
Hospital Germans Trias i Pujol
International Antiviral Society
Institute for Cardiovascular Diseases Dedinje

 

Institute of Biochemistry and Biophysics 
Jena University Hospital
King Abdullah International Medical Research Center
Kanzlei BRENNER
KU Leuven
Leibnitz Institute of Fresh Water and Inland Fisheries
Masaryk University
Max Planck Institute for Evolutionary Biology
McMaster University
Medical University of South Carolina

Medical University of Vienna
Nanyang Technological University

National Institutes of Health
NBT NHS Trust
Queen Astrid Military Hospital
Seoul National University Bundang Hospital
Shanghai Public Health Clinical Center
Università degli Studi di Milano
Universitat de València
Université Laval
University Hospital Erlangen
University Hospital Jena
University Hospital of Liège
University of Bologna
Université libre de Bruxelles 

University of California San Diego
University of Copenhagen
University of Gdansk
University of Helsinki
University of Liverpool
University of Milan
University of Pittsburgh
University of Roma Tor Vergata
University of Warsaw
University of Warwick
Victor Babes University of Medicine Timișoara
Waseda University

Yale University
Yıldız Technical University

 

PrecisionPhage Will Be Supporting Targeting Phage Therapy 2024

 

The 7th World Conference Targeting Phage Therapy on June 20-21 in Malta will be held under the support of PrecisionPhage.

They will be showcasing their SaaS platform – Phagenomics, their phage collection of over 1500 strains available for exclusive and non-exclusive licensing and various laboratory services.

PrecisionPhage online platform Phagenomics makes high-quality phage genome bioinformatics easy and accessible for everyone. Phagenomics integrates a suite of proprietary and 3rd party tools for phage genome assembly, annotation, analysis and comparative genomics. The platform enables users to perform genome assembly from raw reads followed by automated contig selection, genome reorientation, polishing, cross-database and AI based annotations, identification of antibiotic resistance and virulence genes, lyticity prediction, taxonomic classification and more. Additionally, Phagenomics offers features for comparing phages through genome alignment, protein clustering, and in the near future, the construction of smart phage therapy cocktails through our CocktailShaker algorithm.

PrecisionPhage aims to be a comprehensive collaborative partner in the establishing phage ecosystem. Their laboratory services include DNA-isolation, sequencing and analysis services (even for larger Phage Banks), custom phage isolation – a tailored service to discover and characterize phages for a variety of needs, and small-scale phage production. Also, they offer access to their extensive library of over 1500 bacteriophages for research, development, and commercial use, with flexible licensing options.

PrecisionPhage’s team consists of members with decades of research experience, including phage therapy in humans and animals. They are committed to collaborating with institutions and businesses alike to help them reach their project goals. PrecisionPhage is open for partnering in diverse projects and objectives, ultimately bringing phage therapy closer to the people in need.

About PrecisionPhage

PrecisionPhage Ltd, a Finnish company founded upon two decades of phage research, features a large collection of phages and research services along with Phagenomics, a cutting-edge online platform for bacteriophage genome analysis. With their Phagenomics Software-as-a-Service, all DNA-sequence based phage analyses, annotations, phage product validations, genomic comparisons, phage cocktail designs and other steps in therapeutic use and academic research can be done by anyone. They are a comprehensive partner for research and development within the establishing phage ecosystem.

Company website: www.precisionphage.com

Phagenomics website: www.phagenomics.net


Targeting Phage Therapy 2024
7th World Conference
June 20-21, 2024 – Corinthia Palace, Malta

Targeting Phage Therapy 2023 Abstracts Book

 

Phage Therapy 2023 abstracts book includes all this year’s abstracts:

  • 25 major talks
  • 19 short orals
  • 27 posters

Purchase Abstract Book.


Phage Therapy 2023 Replay Access + Abstracts Book

Benefit from both the Abstract Book and Recorded Sessions of Phage Therapy 2023 to stay tuned about all phage therapy novelties and not to miss out on the latest innovations and discovery in the vast world of phage applications.

Order the abstract book and recordings.

Concluding Remarks Awards of Phage Therapy 2016

TID awards

Phage Therapy World Congress 2016 took place at Hotel Saint James Albany, Paris on June 2-3. The congress have welcomed more than 150 academics and industrials attendees coming from 21 countries, from Europe, Asia, Middle East, North and South America.

Phage Therapy 2016 was an exciting moment, where speakers and participants shared scientific knowledge.


At the end of the congress, several awards were discerned:

 

Prof. Martin Witzenrath, from Charité – Universitätsmedizin Berlin, Germany, was awarded for his scientific contribution regarding the phage therapy and especially about Bacteriophage therapy for lung infections.

Prof. Witzenrath, physician and researcher, dedicates his scientific work to the development of novel therapeutic options for lung diseases, including pneumonia, acute respiratory distress syndrome, pulmonary hypertension and asthma. Using experimental in vitro, ex vivo and in vivo techniques, his group aims at translating novel achievements of basic science into clinical perspectives. One of the current projects aims at providing scientific evidence for the use of bacteriophages produced under GMP conditions against multiresistant gramnegative bacteria. Preclinical evaluation is currently performed, and randomized, double-blind, placebo-controlled clinical studies are planned.

 

 

Minmin Yen is currently a PhD candidate in microbiology at Tufts University, Sackler School of Graduate Biomedical Sciences. She was awarded for her short oral presentation regarding the Impact of virulent bacteriophages on vibrio cholerae infection and their use in preventing cholera.

Minmin Yen is completing her thesis research in the laboratory of Andrew Camilli, where she is investigating the population dynamics between Vibrio cholerae, the bacterium that causes cholera, and virulent bacteriophages. Her current work shows that a bacteriophage cocktail is successful in preventing cholera disease in two animal models when administered up to 24 hours prior to V. cholerae infection. Following her graduation, Minmin will continue her bacteriophage cocktail work in the Camilli Lab as well as pursue a Master’s in Public Health at Boston University. In the future, she hopes to combine her background in biological engineering and microbiology to reduce health inequities around the world.

 

 

Dr Felix Broecker from Max Planck Institute, Germany, was awarded for his poster presentation about Microbiota and virome changes after fecal transplantation for Clostridium difficile infection in a “Zurich patient”.

Dr Broecker research aims at understanding the role of phages during fecal microbiota therapy (FMT) against Clostridium difficile infections. FMT is a promising therapeutic option for this deadly disease, as antibiotic resistance is emerging. It has recently been shown that human feces contain ten times more phages than bacteria that are transmitted from donor to patient during FMT, implying that this procedure is largely a phage therapy approach. Although phages are known to regulate bacterial populations and to mediate intestinal inflammation, their contributions to C. difficile infection and FMT-mediated cure remain elusive. Together with colleagues from the University of Zurich and the ETH Zurich, we tackle these questions by characterizing fecal viromes (“phageomes”) of C. difficile patients and donors to identify crucial phages that may be harnessed for targeted phage therapy.

Testimonial from Dr Broecker:
“Phage therapy approaches against various indications are currently on the verge of clinical implementation. Yet, clinical application of phages against C. difficile infections and other intestinal diseases requires detailed knowledge on their dynamics in this complex microbial ecosystem. I am therefore grateful that my studies on phages during C. difficile infection and cure were honored by this prestigious award as well as the great interest by esteemed colleagues during the congress. The recognition encourages me to pursue my work that I hope will ultimately benefit patients suffering from this disease.”

 

 

Dr Alexander Zurabov received the industrial contribution award with his company “MicroMir”.

Dr Zurabov training is in economic cybernetics and he got  his PhD in 1986 for applied mathematics in economics.  Having accumulated extensive experience in various businesses (from banking to civil aviation) in 1990-2004  Alexander Zurabov undertakes since then a task of support and promote innovative ventures in biotechnology, microbiology, medicine and some other areas. Today he is the major stakeholder and investor in several enterprises: Scientific and Research Center “MicroMir”, Moscow (bacteriophage therapy), Stem Cell bank “Pokrovsky”, St. Petersburg (cord blood bank and regenerative therapy medical center), Moscow Insurance company MAKS (general and medical insurance) and others. Alexander Zurabov is the CEO of “Micromir” since its inception ans sees his role in bringing basic and applied research in bacteriophages conducted by leading russian specialists in this area Eugene Zhilenkov and Valentina Popova and their team to clinical practice in Russia and beyond.

To access to the final program of Phage Therapy 2016, please click here.

 phage therapy 2016 pictures
You can find here some pictures of this two-days congress.

Phage Therapy 2023 Concluding Remarks: Future Perspectives

The 6th World Congress on Targeting Phage Therapy 2023 that was held on June 1-2 in Paris, and gathered more than 150 attendees from 30+ different countries. Targeting Phage Therapy 2023 included more than 71 presentations between major talks, short orals, and posters.

The president of Phage Therapy 2023, Prof. Domenico Frezza, and the chairman of the scientific committee, Prof. Marvin Edeas, stated: “It’s wonderful to hear that the speakers at the Targeting Phage Therapy 2023 conference delivered excellent presentations on a variety of fantastic topics. The fact that new findings and original results were shared suggests that the field of phage therapy is advancing and contributing to the development of a new kind of medicine. Phage therapy holds immense potential in addressing the challenge of antibiotic resistance and improving treatment options for bacterial infections. The research and discussions presented at the conference likely showcased the progress and possibilities of this innovative therapeutic approach.”

The Future of Phages

Dr. Marvin Edeas presented a talk on phages and microbiota, he commented, Phages have the potential to play a significant role in shaping our microbiota and influencing various effects within our bodies. The human microbiota, which consists of trillions of microorganisms including bacteria, viruses, and phages, is known to have a profound impact on our health and well-being. Phages, being viruses that specifically target bacteria, can modulate the composition and dynamics of the microbiota by selectively infecting and killing certain bacterial species. This process, known as “phage predation,” can lead to shifts in bacterial populations and the overall balance of the microbiota.

Furthermore, phages can impact the functions and interactions within the microbiota. They can transfer genes between bacteria through a process called horizontal gene transfer, influencing the genetic makeup and capabilities of bacterial communities. This transfer of genetic material can contribute to the spread of antibiotic resistance genes or confer beneficial traits to bacteria, such as the ability to digest certain substances or resist pathogens.

Phages can also have indirect effects on human health by modulating the immune system. They can interact with immune cells and trigger immune responses, potentially influencing immune function and the body’s ability to respond to infections or diseases.

Overall, the interplay between phages, bacteria, and the human microbiota is a complex and fascinating area of research. Understanding and harnessing the power of phages in modulating the microbiota holds great potential for developing innovative therapeutic approaches, improving health outcomes, and addressing various health challenges.

What about Phage and Non-Infectious Disease?

Dr. Edeas strongly convinced that the potential applications of phages extend beyond their traditional use in treating bacterial infections. Emerging research suggests that phages could have therapeutic implications in a variety of non-infectious diseases, including obesity, cancer, and even mental health conditions like depression. However, it’s important to note that while these possibilities are being explored, the field is still in its early stages, and more research is needed to fully understand the mechanisms and effectiveness of phage therapy in these areas.

Targeting Phage Therapy 2023 Awards

Four Awards were decerned. Here’s a summary of the recognized presenters and their contributions:

I. Martha Clokie (University of Leicester, United Kingdom) received the Phage Therapy 2023 Best Scientific Contribution award. Her presentation titled “Challenges and Opportunities for Bacteriophage Therapy” focused on her team’s work in an agricultural setting. She highlighted the insights gained in terms of safety, efficacy, dosing, and the use of phages to target urinary tract pathogens. Clokie emphasized that bacteriophage therapy shows promise in addressing antibiotic resistance and improving treatment options for bacterial infections and microbiome manipulation.

II. Amanda (Curtis) Burkardt, the CEO of PHIOGEN (USA), was awarded the Phage Therapy 2023 Best Scientific Innovation for their technology platform. Burkardt’s presentation titled “Creating Patient Ready Products in a Remedy Ready World” highlighted PHIOGEN’s proprietary technology platform. This platform enables the discovery, screening, and evolution of naturally occurring bacteriophages with exceptional bacteria-fighting abilities. It allows the development of antimicrobials that can overcome resistance. This innovation offers a new business model for phage therapy, enabling the creation of products that can treat entire populations instead of individual patients.

III. The Phage Therapy 2023 Best Short Oral award went to Brieuc Van Nieuwenhuyse from UC Louvain, Belgium. His presentation focused on “Bacteriophage-Antibiotic Combination Therapy Against Extensively Drug-Resistant Pseudomonas Aeruginosa Infection to Allow Liver Transplantation in a Toddler.” Dr. Van Nieuwenhuyse emphasized the importance of considering bacteriophage therapy as a therapeutic option to combat antimicrobial-resistant bacterial infections, particularly in cases where traditional medical practitioners may overlook this potential solution.

IV. The Targeting Phage Therapy 2023 Best Poster award was given to Pantiora Panagiota from the Agricultural University of Athens, Greece. Her poster presentation was titled “Thermostable Bactericidal Endolysin Discovery: New Ways to Fight Bacterial Pathogens – Metagenomics Analysis for the Discovery of a Thermostable Endolysin With High Bactericidal Activity.” This research likely focused on the discovery and potential application of a thermostable endolysin, which is an enzyme that can degrade the cell walls of bacteria, leading to their destruction.

Current challenges and future prospects:

While phage therapy shows great promise, there are still challenges to overcome before it becomes widely available.

  • Regulatory hurdles: Regulatory frameworks for phage therapy vary across different countries, and establishing standardized guidelines is essential.
  • Phage selection: Identifying the most effective phages for specific bacterial strains can be time-consuming and complex.
  • Clinical trials: Rigorous clinical trials are needed to evaluate the safety and efficacy of phage therapy in different patient populations.

Despite these challenges, phage therapy holds significant potential. Ongoing research aims to optimize phage therapy protocols, develop phage cocktails, and improve delivery mechanisms to enhance its efficacy. Phage therapy, in combination with other advances in personalized medicine and immunotherapy, could revolutionize the treatment of bacterial infections and shape the future of medicine.

How phage therapy could influence the future of medicine:

  1. Antibiotic Resistance: The global health community is grappling with the increasing prevalence of antibiotic resistance. As more bacteria evolve resistance to our current arsenal of antibiotics, the effectiveness of these treatments decreases. Phage therapy could offer a solution to this problem as phages are capable of infecting and killing even antibiotic-resistant bacteria.
  2. Precision Medicine: Phages are highly specific to the bacterial strains they infect. This means they could potentially be used for more targeted therapies than broad-spectrum antibiotics, which can disturb the gut microbiota and lead to side effects. This specificity aligns with the broader trend towards precision medicine, which aims to tailor treatment to individual patients based on their unique genetic, environmental, and lifestyle factors.
  3. Phage Therapy Research: There is a resurgence of interest in phage therapy research due to the mounting crisis of antibiotic resistance. This research is producing promising results, but there are still many challenges to be overcome. These include determining the safety and efficacy of phage therapy, regulatory and manufacturing hurdles, and the need for more controlled clinical trials.
  4. Bioengineering: With advancements in biotechnology, it is possible to genetically modify phages or engineer synthetic ones. This could allow us to create phages that are even more effective at combating bacteria, or that carry genes which make bacteria more susceptible to other treatments.
  5. Diagnostics: Phages can be used to detect specific bacteria in diagnostic tests. This could help clinicians identify the cause of an infection more quickly and accurately, leading to more effective treatment.
  6. Environmental applications: Besides human health, phage therapy can also be used in agriculture to combat bacterial diseases in crops or farm animals, and in food safety to kill foodborne pathogens.

While phage therapy holds great promise, it’s important to note that much more research is needed to understand how best to use phages in a clinical setting. Phages are incredibly diverse and complex, and our understanding of phage-bacteria interactions is still in its infancy. It’s also crucial to consider potential risks and challenges, such as the possibility of bacteria developing resistance to phages, the potential for phages to transfer harmful genes between bacteria, and the need for robust regulation and quality control in phage production.


For those interested in accessing the materials and videos from the conference, the organizers offer the opportunity to request access to the replay and abstracts book. Additionally, conference recordings are available on demand for a period of three weeks. This allows participants and others interested in the field of phage therapy to catch up on the details and insights shared during the conference.

Conference Materials and Replay.


Targeting Phage Therapy 2023 Congress
6th World Conference Conclusion
June 1-2, 2023 – Paris, France


Phage Therapy 2023 Videos on Demand


Phage Therapy 2023 Replay Access 

You can catch up on all the details of the 6th World Conference of Targeting Phage Therapy by requesting access to the conference recordings for the period of 3 weeks. 

The conference replay includes the 40+ major talks and short orals  presented during the 2 days of Targeting Phage Therapy 2023.

It also comprises the different innovations presented by:

and others..

Order Recordings.


Phage Therapy 2023 Replay Access + Abstracts Book

Benefit from both the Abstract Book and Recorded Sessions of Phage Therapy 2023 to stay tuned about all phage therapy novelties and not to miss out on the latest innovations and discovery in the vast world of phage applications.

Order the abstract book and recordings.